CARM logo

CARM
Carisma Therapeutics Inc

38,796
Mkt Cap
$1.7M
Volume
240,340.00
52W High
$1.27
52W Low
$0.0261
PE Ratio
-0.03
CARM Fundamentals
Price
$0.05
Prev Close
$0.0406
Open
$0.045
50D MA
$0.2406
Beta
0.97
Avg. Volume
20.48M
EPS (Annual)
-$1.46
P/B
-0.04
Rev/Employee
$426,782.61
Loading...
Loading...
News
all
press releases
JPM downgrades Avis Budget after stock rally on recall, tariff impact
Investing.com -- JP Morgan downgraded Avis Budget (NASDAQ:CAR) Group to Neutral from Overweight, saying the stock’s sharp rally since March has outpaced the underlying earnings outlook, while near-term pressures from safety recalls and fading tariff tailwinds weigh on estimates.
investing.com·3mo ago
News Placeholder
More News
News Placeholder
These companies are most likely to surprise in real estate H1 earnings season
Investing.com -- Bernstein expects a mixed but potentially positive first-half earnings season for the European real estate sector, highlighting nine companies that could raise their guidance.
investing.com·3mo ago
News Placeholder
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference PR...
PR Newswire·8mo ago
News Placeholder
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference...
PR Newswire·9mo ago
News Placeholder
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline PR Newswire PHILADELPHIA, Dec. 9...
PR Newswire·11mo ago
News Placeholder
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024 Carisma Therapeutics Presents Promising New...
PR Newswire·11mo ago
News Placeholder
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR...
PR Newswire·1y ago
News Placeholder
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for...
PR Newswire·1y ago
News Placeholder
Carisma Therapeutics Announces Changes to its Board of Directors
Carisma Therapeutics Announces Changes to its Board of Directors Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, Oct. 30, 2024 Appointment of Sohanya Cheng...
PR Newswire·1y ago
News Placeholder
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 PR Newswire PHILADELPHIA, Oct. 4, 2024 PHILADELPHIA, Oct. 4, 2024...
PR Newswire·1y ago

Latest CARM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.